0210
1 year ago
GRTX @0.14 - 0.15 fwiw. "...risk/reward is still favorable. 28 mil cash on hand, and laying off over 70% of the workforce and stopping the 2 trials, should be ample enough money to carry them through all of 2024. Already have made it clear that they don't want to go through another trial for Avasopasem, as it is costly and time consuming, so if you are buying or going long here, you are simply playing[translation: ACCUMULATING, lol ] for one of the possible strategic maneuvers..."
Source: Click here.